Catalyst
Slingshot members are tracking this event:
Selumetinib granted Orphan Drug Designation in the US for adjuvant treatment of differentiated thyroid cancer
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| AZN |
|
|
||||
Additional Information
Slingshot Insights Explained
Catalyst Date
Occurred on:
May 12, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Orphan Drug Designation, Adjuvant Treatment, Differentiated Thyroid Cancer, Dtc, Radioactive Iodine, Kras-mutant, Nsclc, Select-1, Selumetinib
